Aims: We sought to evaluate influences of oxidative stress (OS) on rHuEPO requirements in hemodialysis patients without chronic inflammation.
Methods: Sixty-eight hemodialysis patients and 46 healthy controls underwent measurements plasma levels of antioxidative agents, such as glutathione peroxidase (GPX), superoxide dismutase (SOD), and oxidative compounds including malonyldialdehyde (MDA). We retrospectively analyzed the last 3 months' rHuEPO requirements, iron indices, and CRP levels.
Results: Plasma levels for SOD, GPX, and MDA were 974.4+/-216.4 U/gHb, 44.4+/-13.6 U/gHb, 10.0+/-2.0 nmol/mL, respectively yielding results that were different from healthy controls (P<.0001). Increased OS negatively correlated with hemoglobin levels (P<.0001) and positively correlated with rHuEPO requirements (P<.01). Increased antioxidative capacity positively correlated with hemoglobin levels (P<.0001) and negatively correlated with rHuEPO requirements (P<.0001). For further analyses, hemodialysis patients were subgrouped according to rHuEPO requirements as group I (lowest 1/3, n=23), group II (moderate 1/3, n=23) and group III (highest 1/3, n=22). Group III displayed the highest MDA (P<.05), the lowest SOD (P<.0001), and comparable GPX (P<.05) levels. Group III also had the highest CRP and the lowest albumin levels compared with the others (P<.01).
Conclusion: OS has strong adverse influences on rHuEPO responses of HD patients with "normal" CRP levels, but it should not be forgotten that CRP levels in the "normal" range may still reflect ongoing microinflammation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2007.06.090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Positive response of a hemodialysis patient with pure red cell aplasia on recombinant human erythropoietin therapy to cyclosporine and Roxadustat.
CEN Case Rep
December 2024
Department of Nephrology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Article Synopsis
- Recombinant human erythropoietin (rHuEPO) is used to treat anemia in chronic kidney disease but can lead to a rare condition called EPO-induced Pure Red Cell Aplasia (PRCA), which causes severe anemia and requires stopping EPO therapy.
- In a reported case, a hemodialysis patient developed PRCA despite testing negative for anti-EPO antibodies, and treatment was successfully managed with cyclosporine and maintained using Roxadustat.
- The case highlights the clinical signs of EPO-induced PRCA, the limitations of the antibody assay for diagnosis, and various treatment strategies for managing the condition.
The role of erythropoietin to prevent red blood cell transfusion in a 2018-2020 two-center cohort of preterm infants.
Blood Transfus
July 2024
Department of Neonatology, Caen University Hospital, Université de Caen Normandie, UFR Médecine, Caen, France.
Background: Treatment with recombinant human erythropoietin (rHu-EPO) modestly prevented packed red blood cell transfusions (pRBCTs) in preterm infants in studies performed several years ago. In France, some neonatal units stopped using rHu-EPO, while others continued. The aim of this study was to explore the role of rHu-EPO in the prevention of pRBCTs in a recent cohort of preterm infants.
View Article and Find Full Text PDFMetabolomic Profiling of Recombinant Erythropoietin (rHuEpo) in Trained Caucasian Athletes.
Clin J Sport Med
September 2023
Department of Biochemistry and Molecular Genetics, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Objective: Recombinant human erythropoietin (rHuEpo) is prohibited by the World Anti-Doping Agency but remains the drug of choice for many cheating athletes wishing to evade detection using current methods. The aim of this study was to identify a robust metabolomics signature of rHuEpo using an untargeted approach in blood (plasma and serum) and urine.
Design: Longitudinal study.
Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review.
Clin Kidney J
August 2022
Royal Hospital for Children Glasgow, Paediatric Nephrology, Glasgow, UK.
Background: Erythropoiesis-stimulating agents (ESAs) revolutionized the management of anaemia in chronic kidney disease (CKD) when introduced in the late 1980s. A range of ESA types, preparations and administration modalities now exist, with newer agents requiring less frequent administration. Although systematic reviews and meta-analyses have been published in adults, no systematic review has been conducted investigating ESAs in children.
View Article and Find Full Text PDFErythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.
Pediatr Nephrol
October 2022
Laboratory of Endocrinology, Hospital Donación Francisco Santojanni, Pilar 950, 1408, Ciudad Autónoma de Buenos Aires, Argentina.
Background: The efficacy of recombinant human erythropoietin (rHuEPO) in sparing red blood cell (RBC) transfusions in children with hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli (STEC-HUS) is uncertain.
Methods: We conducted a pilot randomized controlled open trial between December 2018 and January 2021. Children were randomized to the intervention (subcutaneous rHuEPO 50 U/kg three times weekly until discharge + RBC transfusion if hemoglobin ≤ 7 g/dL and/or hemodynamic instability) or to the control arm (RBC transfusion if hemoglobin ≤ 7 g/dL and/or hemodynamic instability).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!